Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC

I Ahrens; J Habersberger; N Baumlin; H Qian; BK Smith; JP Stasch; C Bode; HHHW Schmidt; K Peter

Journal article

Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC

I Ahrens, J Habersberger, N Baumlin, H Qian, BK Smith, JP Stasch, C Bode, HHHW Schmidt, K Peter

Atherosclerosis | ELSEVIER IRELAND LTD | Published : 2011

DOI: 10.1016/j.atherosclerosis.2011.06.042

Abstract

Objective: The soluble guanylate cyclase (sGC) activator Cinaciguat (BAY 58-2667) represents a novel class of drugs that selectively activate oxidised sGC. The extent of oxidised sGC depends on the patient's oxidative burden. We here describe two platelet-based assays that allow determining the extent of oxidised sGC and thus provide a basis for an individualised pharmacotherapy. Methods/Results: Platelets obtained from patients with (n= 12) and without (n= 12) coronary artery disease (CAD) were examined by flow cytometry (P-selectin expression), and Western blots (vasodilator associated phosphoprotein, VASP-phosphorylation). Results were compared to maximal oxidation of sGC achieved by the ..

View full abstract

University of Melbourne Researchers

Hongwei Qian Author

Karlheinz Peter Author

Grants

Awarded by Cardiac Society of Australia and New Zealand

Funding Acknowledgements

This work was supported by the Deutsche Forschungsgemeinschaft [DFG AH 185/1-1 to I.A.], by the National Health and Medical Research Council of Australia [K.P, J.H., N.B., B.K.S., H.H.H.W.S.] and by the Cardiac Society of Australia and New Zealand [J.H.].